{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:50:21Z","timestamp":1782132621204,"version":"3.54.5"},"reference-count":15,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v106.adv-2026-0380","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:11:22Z","timestamp":1782130282000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4832-1899","authenticated-orcid":false,"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"159631","doi-asserted-by":"crossref","unstructured":"Pereira MP, Hoffmann V, Weisshaar E, Wallengren J, Halvorsen JA, Garcovich S, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol 2020; 34: 2373\u20132383.","DOI":"10.1111\/jdv.16309"},{"key":"159632","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Pereira MP, Misery L, Mollanazar NK, Shah P, Wiggins S. Prurigo nodularis: disease burden, clinical features and approach to management. Br J Dermatol 2025; 193: 642\u2013652.","DOI":"10.1093\/bjd\/ljaf213"},{"key":"159633","doi-asserted-by":"crossref","unstructured":"Igarashi A, Yoshida T, Sunaga Y, Nawata H, Arima K. Current status of prurigo nodularis in Japan: a retrospective study using a health insurance claims database. J Clin Med 2025; 14: 1872.","DOI":"10.3390\/jcm14061872"},{"key":"159634","doi-asserted-by":"crossref","unstructured":"Waitek M, Weisshaar E. The epidemiology of chronic prurigo: lessons learned. Acta Derm Venereol 2025; 105: adv44334.","DOI":"10.2340\/actadv.v105.44334"},{"key":"159635","doi-asserted-by":"crossref","unstructured":"Murota H, Matsumoto M, Arima K, Yoshida T, Fujita H. Current clinical practice of prurigo nodularis in Japan: a cross-sectional web-survey among dermatologists. J Dermatol 2025; 52: 348\u2013352.","DOI":"10.1111\/1346-8138.17400"},{"key":"159636","doi-asserted-by":"crossref","unstructured":"Murota H, Arima K, Yoshida T, Fujita H. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan. J Dermatol 2024; 51: 223\u2013233.","DOI":"10.1111\/1346-8138.17045"},{"key":"159637","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180\u20131190.","DOI":"10.1038\/s41591-023-02320-9"},{"key":"159638","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A, et al. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 2022; 36: 1820\u20131825.","DOI":"10.1111\/jdv.18377"},{"key":"159639","doi-asserted-by":"crossref","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O\u2019Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation. J Invest Dermatol 2025; 145: 249\u2013256.","DOI":"10.1016\/j.jid.2024.06.1276"},{"key":"159640","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579\u20131589.","DOI":"10.1056\/NEJMoa2301333"},{"key":"159641","unstructured":"Legat FJ, Kwatra SG, Reich A, Boulinguez S, Tsianakas A, Sauder M, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol 2025."},{"key":"159642","doi-asserted-by":"crossref","unstructured":"Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502\u2013507.","DOI":"10.2340\/00015555-1246"},{"key":"159643","doi-asserted-by":"crossref","unstructured":"Zeidler C, Pereira MP, Augustin M, Spellman M, St\u00e4nder S. Investigator\u2019s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol 2021; 101: adv00401.","DOI":"10.2340\/00015555-3701"},{"key":"159644","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med 2025; 14: 3026.","DOI":"10.3390\/jcm14093026"},{"key":"159645","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. The absence of recent systemic therapy can be a significant risk factor for nemolizumab-associated cutaneous adverse events in patients with prurigo nodularis: a single-centre retrospective study. Acta Derm Venereol 2025; 105: adv44310.","DOI":"10.2340\/actadv.v105.44310"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46371\/54432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46371\/54433","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46371\/54434","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46371\/54432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:11:51Z","timestamp":1782130311000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":15,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0380","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}